James Abbruzzese is an Oncology physician affiliated with Duke Medical Center. OpenAlex indexes 784 publications with 59,211 citations (h-index 129); ClinicalTrials.gov lists 3 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Medical Oncology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1515 Holcombe Blvd
Houston, TX 770304009
Telephone
713-792-6161Registry record last updated 29 Jun 2012.
Clinical trials
- S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer
Sponsor: SWOG Cancer Research Network
- S0304 Induct Chemo Then Chemo-RT in Pts w/Locally Advanced Adenocarcinoma of the Rectum
Sponsor: SWOG Cancer Research Network
- SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer
Sponsor: National Cancer Institute (NCI)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Baxter HealthcareProgram year20243 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
58%Serotonin-3 Receptor Antagonist40.6%Ondansetron Hcl100%Part D≥12 patientsProton pump inhibitor17.4%Omeprazole100%Part D<11 patientsNervous system
26.1%Phenothiazine26.1%Prochlorperazine Maleate100%Part D≥12 patientsBlood & clotting
15.9%Factor Xa inhibitor15.9%Eliquis100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
5 NIH research awards on record, funded 1991–2009 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Use of Research Biopsies in Clinical Trials: Are Risks and Benefits Adequately Discussed?
Journal of Clinical Oncology
2012 - Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer
Clinical Cancer Research
2012
Similar KOLs
Other experts from the same institution or the same specialty.
David Durack, MD
Duke Medical Center
Leonard Prosnitz, MD
Duke Medical Center
Scott Cousins, MD
Duke Medical Center
Brian Czito, MD
Duke Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”